InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes

If you would like to register, please email 2 preferred usernames to oceanfisher@gmail.com. You will be registered and sent instructions.
To start viewing messages,
select the forum that you want to visit from the selection below.

NEW YORK, NY--(Marketwire -11/21/11)- The stem cell industry lost one of its key players earlier this month when industry pioneer Geron Corporation announced its intention to exit the stem cell research market. The company, which was a leader in stem cell research, intends to focus on its oncology programs instead. Geron's exit has left not only the stem cell industry more wide open, but also the spinal cord injury treatment sector. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investmhttp://finance.yahoo.com/news/invivo-therapeutics-cord-blood-america-131600442.htmlent research on InVivo Therapeutics Corporation (OTC.BB: NVIV.OB - News) and Cord Blood America Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at:

NEW YORK, NY--(Marketwire -11/21/11)- The stem cell industry lost one of its key players earlier this month when industry pioneer Geron Corporation announced its intention to exit the stem cell research market. The company, which was a leader in stem cell research, intends to focus on its oncology programs instead. Geron's exit has left not only the stem cell industry more wide open, but also the spinal cord injury treatment sector. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investmhttp://finance.yahoo.com/news/invivo-therapeutics-cord-blood-america-131600442.htmlent research on InVivo Therapeutics Corporation (OTC.BB: NVIV.OB - News) and Cord Blood America Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at: